Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney - a Phase II Clinical Trial

Surgery is the standard treatment for primary kidney cancer, however, in some cases surgery is either not possible or other health problems make surgery high risk. This study involves a relatively new, highly precise multidirectional radiotherapy technique called Stereotactic Ablative Body Radiotherapy (SABR) and all participants will receive this radiotherapy technique. The aim of the study is to test the ability of this technique to control the cancer within the kidney for those people where surgery is not an option, as well as to examine the side effects of the treatment, including how it may affect your kidney’s function.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Final Accrual

71

Closing Date of Accrual

2nd March 2020

Trial Chairperson

A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC

Trial Contact

FASTRACKII@trog.com.au

Clinical Trial Registration

Related Post

14 April, 2026

Consumer Engagement Charter cements TROG’s commitment to listen to consumer voices

LATEST NEWS: 14 April 2026 TROG has made a

9 April, 2026

Vale Professor Jim Denham OAM, TROG founder and world-class researcher

9 April 2026 TROG Cancer Research honours the life